Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women

Seminars in Oncology

Volumn 36, Issue 6, 2009, Pages 566-571

  Chlebowski, Rowan T ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PLACEBO;

ARTICLE; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; HORMONE SUBSTITUTION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MENOPAUSAL SYNDROME; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LUNG NEOPLASMS; MEDROXYPROGESTERONE; RECEPTORS, ESTROGEN; WOMEN'S HEALTH;

EID: 71049145346     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.10.008     Document Type: Article

References (49)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics 2008. Ca Cancer J Clin 58 (2008) 71-96
2. Fu J.B., Kau T.Y., Severson R.K., and Kalmekerian G.P. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 127 (2005) 768-777
3. Radzikowska E., Glaz P., and Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13 (2002) 1087-1093
4. Visbal A.L., Williams B.A., Nichols F.C., Marks R.S., Jett J.R., Aubry M.C., et al. Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 78 (2004) 209-215
5. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., and Calle E.E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98 (2006) 691-699
6. Marquez-Garban D.C., Chen H.W., Goodglick L., Fishbein M.C., and Pietras R.J. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann NY Acad Sci 115 (2009) 194-205
7. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., and Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 61 (2005) 1459-1470
8. Omoto Y., Kobayashi Y., Nishida K., Tsuchiya E., Eguchi H., Nakagawa K., et al. Expression, function, and clinical implimentations of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285 (2001) 340-347
9. Niikawa H., Suzuki T., Miki Y., Suzuki S., Nagasaki S., Akahira J., et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14 (2008) 4417-4426
10. Schabath M.B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A.A., and Spitz M.R. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10 (2004) 113-123
11. Kruezer M., Gerken M., Heinrich J., Kreienbrock L., and Wichmann H.E. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol 32 (2003) 263-271
12. Taioli E., and Wynder E.L. Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (1994) 869-870
13. Liu Y., Inoue M., Sobue T., and Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 117 (2005) 662-666
14. Chlebowski R.T., Palomares M.R., Lillington L., and Grosvenor M. Recent implications of weight loss on lung cancer management. Nutrition 12 (1996) S43-S47
15. Ou S.I., Ziogas A., and Zell J.A. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): high percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. [abstract 8004]. J Clin Oncol 26 suppl 15 (2008) 425s
16. Wisnivesky J.P., and Halm E.A. Sex differences in lung cancer survival: do tumors behave differently in elderly women. J Clin Oncol 25 (2007) 1705-1712
17. Wakelee H.A., Dahlberg S.E., Schiller J.H., Langer C.J., Sandler A.B., Brahmer J.R., et al. Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. [abstract P1-052]. J Thorac Oncol 8 suppl 4 (2007) S570
18. Albain K.S., Unger J., Gotay C.C., Davies A.M., Edelman M., Herbst R.S., et al. Toxicity and survival by sex in patients with advanced non-small cell lung cancer carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 25 suppl 18 (2007) 7549
19. Ross H., Oldham F.B., Bandstra B., Sandalie L., Bianco J., Bonomi P., et al. Serum-free estradiol (E2) levels are prognostic in men with chemothearpy-naive advanced non-small cell lung cacner (NSCLC) and performance status (PS). J Clin Oncol Am Soc Clin Oncol Ann Proc 25 suppl 15 (2007)
20. Baik C.S., Strauss G.M., and Feskanich D. A prospective study of reproductive factors, hormone use, and risk of lung cancer in postmenopausal women. J Clin Oncol 27 (2009) 1501
21. Olsson H., Bladstrom H., and Ingvar C. Are smoking-associated cancers prevented or postposned in women using hormone replacement therapy?. Obstet Gynecol 102 (2003) 565-570
22. Schwartz A.G., Wenzlaff A.S., Prysak G.M., Murphy V., Cote M.L., Brooks S.C., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
23. Ramnath N., Menezes R.J., Loewen G., Dua P., Eid F., Alkhaddo J., et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of case-control study. Oncology 73 (2007) 305-310
24. Rodriguez C., Spencer Feigelson H., Deka A., Patel A.V., Jacobs E.J., Thun M.J., et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 17 (2008) 655-660
25. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsch V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
26. Thatcher N., Chang A., Parikh P., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer. Lancet 366 (2005) 1527-1537
27. Scagliotti G., Purvish P., von Pawel J., Biesma B., Vansteenkiste J., Mangold C., et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2 (2007) S306 (PRS-03)
28. Ganti A.K., Sahmoun A.E., Panwalker A.W., Tendulkar L.L., and Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
29. Huang B., Carloss H., Wyatt S.W., and Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer 115 (2009) 4167-4175
30. Ayeni O., and Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?. Curr Oncol 16 (2009) 21-25
31. Ettinger B., Friedman G.D., Bush T., and Quesenberry Jr. C.P. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87 (1996) 6-12
32. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19 (1998) 61-109
33. Hays J., Hunt J.R., Hubbell F.A., Anderson G.L., Limacher M., Allen C., et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13 suppl (2003) S18-S77
34. Anderson G.L., Manson J., Wallace R., Lund B., Hall D., Davis S., et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 13 suppl 9 (2003) S5-S17
35. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
36. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289 (2003) 3243-3253
37. Heiss G., Wallace A., Anderson G.L., Aragaki A., Beresford S.A., Brzysk R., et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299 (2008) 1036-1045
38. Chlebowski R.T., Schwartz A., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E., et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post hoc analysis of a randomized controlled trial. Lancet 374 (2009) 1243-1251
39. Ravdin P.M., Cronin K.A., Howlander N., Chlebowski R.T., and Berry D.A. A sharp decrease in breast cancer incidence in the United States in 2003. [abstract]. Breast Cancer Res Treat 100 suppl (2006) S2
40. Clarke C.A., Glaser S.L., Uratsu S.L., Selby J.V., Kushi L.H., and Herrington L.J. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24 (2006) 49e-50e
41. Chlebowski R.T., Kuller L., Prentice R.L., Stefanick M.L., Manson J.E., Gass M., et al. Breast cancer after estrogen plus progestin use in postmenopausal women. N Engl J Med 360 (2009) 573-587
42. Losordo D.W., and Isner J.M. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 21 (2001) 6-12
43. Dobrzycka B., Kinalski M., Piechocka D., and Terlikowski S.J. The role of estrogens in angiogenesis in the female reproductive system. Endokrynol Pol 60 (2009) 210-214
44. Calvo A., Catena R., Noble M.S., Carbott D., Gil-Bazo I., Gonzalez-Moreno O., et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 27 (2008) 5373-5384
45. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
46. Wu C.Y., Change Y.L., Shih J.Y., and Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130 (2005) 979-986
47. Kawai H., Ishii A., Washiya K., Kon H., Yamaya C., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11 (2005) 5084-5089
48. Nose N., Sugio K., Oyama T., Nozoe T., Uramoto H., Iwata T., et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27 (2009) 411-417
49. Raso M.G., Behrens C., Herynk M.H., Liu S., Prudkin L., Ozburn N.C., et al. Immunohistochemical expression of estroegn and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15 (2009) 5359-5368